US4469681A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method and system for the controlled release of biologically active substances to a body fluid
Assignee: Rockefeller University
•
Filing: 1981-06-29
•
Granted: 1984-09-04
•
Expires: 2001-06-29
Abstract
Abstract A process and system for controlled delivery of a biologically active substance to an animal body fluid which comprises contacting fluid with a reversible complex of a conjugate (1) and a binding macromolecule (2), wherein the conjugate (1) comprises a biologically active portion which is intended to be proportionately released into a body fluid stream in response to varying concentration levels of a component of the body fluid stream, and a complexing substrate portion which conjugates with the biologically active portion and which is characterized by affinity to the binding macromolecule (2), competitivey or non-competitively with the variable component of the body fluid; thereby causing the component present in the body fluid to complex to the binding macromolecule and thus releasing the conjugate (1) therefrom into the fluid. The process and system are particularly applicable for the glucose-controlled release of insulin and other hypoglycemic agents in the treatment of diabetes.
Inventors
- 👤 Michael Brownlee
- 👤 Anthony Cerami
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 21:06
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/22; A61K38/28; A61K47/00; A61K47/50; A61K47/51; A61K47/62; A61K47/64; A61K47/6415; A61M; A61M31/00; A61M31/002
Claims Analysis
Total Claims: 20
Claim 1
Independent Claim
77 words
A process of treating hyperglycemia, which comprises: delivering, from a dialysis tube to a glucose containing human body fluid, a reversible complex of (1) a hypoglycemically active insulin analogue which is a conjugate between a carbohydrate and an insulin and (2) a lectin having affinity for glucose and for the carbohydrate portion of said conjugate (1); thereby causing the glucose present in said fluid to complex to said lectin and to release said conjugate into said fluid.
Claim 2
Dependent Claim
77 words
A process of treating hyperglycemia, which comprises: delivering, from a dialysis tube to a glucose containing human body fluid, a reversible complex of (1) a hypoglycemically active insulin analogue which is a conjugate between a carbohydrate and an insulin and (2) a lectin having affinity for glucose and for the carbohydrate portion of said conjugate (1); thereby causing the glucose present in said fluid to complex to said lectin and to release said conjugate into said fluid.
Claim 3
Dependent Claim
15 words
The process of claim 1 wherein said lectin (2) is immobilized in said dialysis tube.
Claim 4
Dependent Claim
22 words
The process of claim 1 wherein said dialysis tube is present in a device implanted externally or internally to the human body.
Claim 5
Dependent Claim
16 words
The process of any of claims 1, 2 or 3 wherein said lectin in concanavalin A.
Claim 6
Dependent Claim
15 words
The process of any of claims 1, 2 or 3 wherein said carbohydrate is maltose.
Claim 7
Dependent Claim
26 words
The process of any of claims 1, 2 or 3 wherein said reversible complex comprises at least two conjugates or different affinity towards said lectin (2).
Claim 8
Dependent Claim
25 words
The process of any of claims 1, 2 or 3 wherein said reversible complex comprises at least two conjugates with two different hypoglycemically active portions.
Claim 9
Dependent Claim
24 words
The process of any of claims 1, 2 or 3 wherein said carbohydrate is a manno-oligosaccharide containing from 2 to 7 (1→2) α-D-mannopyranosyl residues.
Claim 10
Dependent Claim
31 words
The process of any of claims 1, 2 or 3 wherein said insulin carbohydrate conjugate is such that not all three primary amino groups of insulin are substituted by said carbohydrate.
Claim 11
Dependent Claim
56 words
A controlled release medication which comprises: a hypoglycemically active amount of a reversible complex of (1) a hypoglycemically active insulin analogue which is a conjugate between a carbohydrate and an insulin and (2) a lectin having affinity for glucose and for the carbohydrate portion of said conjugate; wherein said complex is present in a dialysis tube.
Claim 12
Dependent Claim
56 words
A controlled release medication which comprises: a hypoglycemically active amount of a reversible complex of (1) a hypoglycemically active insulin analogue which is a conjugate between a carbohydrate and an insulin and (2) a lectin having affinity for glucose and for the carbohydrate portion of said conjugate; wherein said complex is present in a dialysis tube.
Claim 13
Dependent Claim
13 words
The medication of claim 10 wherein said complex is immobilized in said tube.
Claim 14
Dependent Claim
22 words
The medication of claim 10 wherein said dialysis tube is present in a device implanted externally or internally in the human body.
Claim 15
Dependent Claim
16 words
The medication of any of claims 10, 11 or 12 wherein said lectin in concanavalin A.
Claim 16
Dependent Claim
15 words
The medication of any of claims 10, 11 or 12 wherein said carbohydrate is maltose.
Claim 17
Dependent Claim
26 words
The medication of any of claims 10, 11 or 12 wherein said reversible complex comprises at least two conjugates (1) having different affinity towards said lectin.
Claim 18
Dependent Claim
24 words
The medication of any of claims 10, 11 or 12 wherein said reversible complex comprises at least two conjugates with different hypoglycemically active portions.
Claim 19
Dependent Claim
24 words
The medication of any of claims 10, 11 or 12 wherein said carbohydrate is a manno-oligosaccharide containing from 2 to 7 (1→2) α-D-mannopyranosyl residues.
Claim 20
Dependent Claim
30 words
The medication of any of claims 10, 11 or 12 wherein said insulin/carbohydrate conjugate is such that not all three primary amino groups of insulin are substituted by said carbohydrate.
References Cited (Backward Citations)
US4003792A
Cited
US3549409A
Cited
US3673612A
Cited
DE2054446A1
Cited
US3857393A
Cited
US3847890A
Cited
FR2298832A1
Cited
US4239664A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-09-04 | 1988-03-05 | 1988-09-04 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-09-04 | 1992-03-05 | 1992-09-04 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-09-04 | 1996-03-05 | 1996-09-04 | $7700.00 | Window Closed / Lapsed |